Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants

Table 1 Demographic and clinicopathologic characteristics of patients n (%)

	Follow up (yr)		Total (n = 201)	P value
	Before 2008 (n = 127)	2008-2010 (n = 74)
Demographics
Age (yr), mean ± SD	56.7 ± 12.7	54.7 ± 10.3	56.0 ± 11.9	0.2701
Gender
Female	36 (28.3)	25 (33.8)	61 (30.3)	0.4192
Male	91 (71.7)	49 (66.8)	140 (69.7)
Clinicopathologic characteristics
Pathological type
AdenoCa	92 (72.4)	39 (52.7)	131 (65.2)	0.0012
Signet ring	33 (26.0)	31 (41.9)	64 (31.8)
Squamous	2 (1.6)	0	0
Mucinous	0	4 (5.4)	4 (2.0)
Tumor size
< 5 cm	49 (43.0)	28 (47.5)	77 (44.5)	0.0552
5-10 cm	60 (52.6)	23 (39.0)	83 (48.0)
> 10 cm	5 (4.4)	8 (13.6)	13 (7.5)
Tumor location
Antrum	56 (44.8)	37 (51.4)	93 (47.2)	0.2492
Cardia	29 (23.2)	15 (20.8)	44 (22.3)
Corpus	37 (29.6)	15 (20.8)	52 (26.4)
> 1 region	3 (2.4)	5 (6.9)	8 (4.1)
Differentiation
Well	2 (1.7)	1 (1.8)	3 (1.7)	0.8852
Moderate	41 (35.3)	18 (31.6)	59 (34.1)
Poor	73 (62.9)	38 (66.7)	111 (64.2)
Surgery type
Total gastrectomy	64 (50.4)	37 (50.0)	101 (50.2)	0.9572
Subtotal gastrectomy	63 (49.6)	37 (50.0)	100 (49.8)
Surgical margin
Negative	114 (89.8)	61 (82.4)	175 (87.1)	0.1352
Positive	13 (10.2)	13 (17.6)	26 (12.9)
Vascular involvement	81 (64.8)	58 (80.6)	139 (70.6)	0.0333
Perineural involvement	80 (64.0)	52 (72.2)	132 (68.4)	0.4263
TM stage
T1T2	40 (31.5)	23 (31.1)	63 (31.3)	0.9512
T3T4	87 (68.5)	51 (68.9)	138 (68.7)
Nodal stage
N0	30 (24.2)	12 (16.7)	42 (21.4)	0.2542
N1	55 (44.4)	26 (36.1)	81 (41.3)
N2	26 (21.0)	24 (33.3)	50 (25.5)
N3	13 (10.5)	10 (13.9)	23 (11.7)
AJCC 2002 nodal stage
N0	32 (25.2)	14 (18.9)	46 (22.9)	0.3642
N1	62 (48.8)	35 (47.3)	97 (48.3)
N2	26 (20.5)	15 (20.3)	41 (20.4)
N3	6 (4.7)	8 (10.8)	14 (7.0)
NX	1 (0.8)	2 (2.7)	3 (1.5)
AJCC 2010 nodal stage
N0	32 (25.2)	14 (18.9)	46 (22.9)	0.2312
N1	32 (25.2)	12 (16.2)	44 (21.9)
N2	31 (24.4)	23 (31.1)	54 (26.9)
N3a	25 (19.7)	15 (20.3)	40 (19.9)
N3b	6 (4.7)	8 (10.8)	14 (7.0)
Nx	1 (0.8)	2 (2.7)	3 (1.5)
Dissected lymph nodes, median (IQR)	15 (13.0)	17.5 (13.0)	16 (14.0)	0.2164
LN1
< 15	66 (52.4)	30 (40.5)	96 (48.0)	0.1062
≥ 16	60 (47.6)	44 (59.5)	104 (52.0)
LN2
< 10	38 (30.2)	18 (24.3)	56 (28.0)	0.3752
≥ 11	88 (69.8)	56 (75.7)	144 (72.0)
Involved lymph nodes, median (IQR)	2 (6.0)	4 (7.0)	3 (6.0)	0.0734

¹Student-t test;

²χ² test;

³Fisher-Exact test;

⁴Mann-Whitney U test. AJCC: American Joint Committee on Cancer.